Objective: Known diabetes is an independent predictor for mortality in coronary artery disease (CAD) patients, however, whether other glucose abnormalities are associated with death risk in CAD patients is unclear. The goal of this study was to examine the association between different glucose states and the risks of all-cause and cardiovascular disease (CVD) mortality among CAD patients.
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of alcoholic beverage at least once a week and lasted more than six months. Smoking and drinking status were classified as never, past, or current (21) .
Clinical characteristics, clinical tests' results and treatment of participants were collected from an electronic case record system. At admission, trained nurses measured height, weight and blood pressure using a standard protocol (22) . BMI was calculated by dividing weight in kilograms by the square of height in meters. A venous blood specimen was drawn in the next morning after hospital admission with at least 12 hours fasting. Lipids and fasting plasma glucose (FPG) were determined by standard methods. Glomerular filtration rate (GFR) was used to assess renal function which was estimated with the most recent MDRD Study equation for standardized serum creatinine (23) , which is estimated GFR (eGFR) = 175 × (standardized serum creatinine in mg/dL) -1.154 × Age -0.203 × 0.742 (if female). Severity of CAD was based on coronary artery stenosis degree of coronary angiography (CAG) reports, which was categorized as not conduct, <50%, 50-74.9%, and ≥75%. Treatment information of CAD included percutaneous coronary intervention (PCI) and coronary artery bypass graft (CABG). Patients without known or newly diagnosed diabetes (n=1054) were asked to conduct a standard 2-hour oral glucose tolerance test (OGTT) when they were in a stable condition. An OGTT was measured in 643 patients. The results of the OGTT, or FPG only when OGTT wasn't conducted, were used to categorize patients. mmol/L. In addition, subjects were also classified into four groups based on FPG only: known diabetes; newly diagnosed diabetes, FPG ≥7.0 mmol/L; IFG, FPG 5.6-6.9 mmol/L; and normoglycemia, FPG <5.6 mmol/L.
Glucose states

Prospective follow-up
Follow-up data were collected from hospitals' medical records of readmission, telephone contacts with patients or family members, and death registration of Guangdong Provincial Center for Disease Control and Prevention. The surveys were followed to the end of July 2013 or patients' death, whatever occurred first. The ICD codes were used to code the cause of death, and the ICD codes I00-I99 were classified as CVD deaths.
Statistical analysis
Differences in risk factors by different glucose states were analyzed by the general linear model after adjustment for age and sex. The associations between baseline glucose status (normoglycemia, IGR/IFG, newly diagnosed diabetes, and known diabetes) and the risks of allcause and CVD mortality were analyzed by using Cox proportional hazards models. The
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proportional hazards assumption in the Cox model was assessed with graphical methods, and with models including time-by-covariate interactions (25) . In general, all proportionality assumptions were appropriate. All analyses were adjusted for age and sex, and further for education, marriage, smoking, alcohol drinking, leisure-time physical activity, BMI, systolic blood pressure (SBP), total cholesterol, HDL cholesterol, eGFR, types of CAD (acute and chronic), severity of CAD, duration of CAD, treatment of CAD, history of heart failure, and use of antihypertensive, cholesterol-lowering and anti-platelet drugs. For patients without known diabetes, the receiver operator characteristic (ROC) curve analysis was used to evaluate predictive accuracy of continuous FPG and 2-hour glucose level, and the spline plot was used to display continuous associations of FPG with all-cause and CVD mortality. Statistical significance was considered to be P<0.05. All statistical analyses were performed with PASW for Windows, version 20.0 (IBM SPSS Inc, Chicago, III) and SAS for Windows, version 9.3 (SAS Institute, Cary, NC).
Results
Baseline characteristics according to glucose states were presented in Table 1 . Patients with normoglycemia, IGR, newly diagnosed diabetes and known diabetes constituted 31.1%, 23.3%, 21.2%, and 24.4% of whole subjects.
During a median follow-up of 3.1 years, 129 deaths were recorded, 109 of which were due to CVD. The left 20 non-CVD deaths consisted of 14 deaths of cancer and 6 deaths of asphyxia due Owing to part of sample taking OGTT tests, our glucose classification of CAD patients might be challenged. Thus we further conducted analyses based on subjects with both 2-hour glucose and FPG measurements (n=1118). CAD patients with known or newly diagnosed diabetes were still associated with increased risks of all-cause and CVD mortality compared with normoglycemic subjects (Table 3 ).
In the multivariable subpopulation analyses, the association between glucose status and mortality remained similar when participants were stratified by age, gender, BMI, and type of CAD (Supplemental Table S1 ). There were no significant interactions between glucose status and these variables with the risks of all-cause and CVD mortality except for BMI regarding to CVD mortality.
In order to assess the association of continuous FPG level and OGTT results with the risk of mortality, ROC curves and spline plots were used to evaluate the two measurements. ROC curves showed that the area under the curve of FPG and OGTT was more than 0.60, while the area under the curve of OGTT with regard to CVD mortality was not significant due to the small sample size (Supplemental Table S2 ). Spline plots displayed a J-shaped association between 
Conclusions
The present study found that Chinese CAD patients with IFG, newly diagnosed diabetes, and known diabetes were associated with increased risks of all-cause and CVD mortality compared with Chinese CAD patients with normoglycemia. Chinese CAD patients with IGR were also associated with an increased risk of CVD mortality.
The present study found that the prevalence of diabetes and IGR in Chinese CAD patients were 45.4% and 23.3%. Our result was the same as the Euro Heart Survey and the China Heart Survey, which showed that almost half of CAD patients had diabetes and about 25% of CAD patients had IGR (3, 4).
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Only a few studies have assessed the association between hyperglycemia (including known and newly diagnosed diabetes, as well as IGR and IFG) and death risk among CAD patients. The present study indicated that known diabetes, newly diagnosed diabetes and pre-diabetes (IGR or IFG), were independent risk factors of mortality among CAD patients. Several previous studies have confirmed that known diabetes is associated with a high risk of adverse outcome for CAD patients (8, 26) . However, regarding to newly diagnosed diabetes and IGR, previous findings were inconsistent. One Swedish study including 168 patients with acute myocardial infraction has identified that abnormal glucose tolerance (combined newly diagnosed diabetes and IGT) was a prominent risk factor of further cardiovascular events (14) . But with a small sample size (168 patients) this study did not analyze the newly diagnosed diabetes and IGT separately with further cardiovascular risk. In agreement with our results, two early American studies reported that among CAD patients both IFG (FPG 6.1-6.9 mmol/L) and diabetes were associated with an increased risk of mortality compared with normoglycemia (27, 28) . In contrast with our study, they didn't have OGTT measurements, so they couldn't further evaluate the risk of IGT and IGR.
While we used new ADA standards (FPG 5.6-6.9 mmol/L) to define IFG, this threshold still can predict an increased risk of mortality. Displayed by spline plots, we found a J-shaped relationship between the baseline FPG and subsequent death of all-cause and CVD; the cutpoint of increase in the risk was apparent for glucose level which was below current diabetic threshold, even the IFG threshold. This finding was consistent with the previous Diabetes Epidemiology:
Collaborative Analysis Of Diagnostic Criteria in Europe (DECODE) study. In their metaanalysis, there was a J-shaped relation between FPG and mortality of all-cause, CVD, and non-CVD among European general populations. And the thresholds of increase of risk were 5.3mmol/L for all-cause and 5.4 mmol/L for CVD (12) . Thus, our study confirmed the prognostic significance of the current ADA recommendation for the lower IFG threshold in
Chinese patients with CAD. The Euro Heart Survey has found that only CAD patients with both known and newly diagnosed diabetes, but not with IGR, were at high risk of mortality during the 1-year follow-up period (13) . Besides the different ethnicities, there were some other differences in the methods between our study and the Euro Heart Survey, which may result in this contrary conclusion. The Euro Heart Survey only focused on 1-year outcome, which may not be long enough to observe the difference in prognosis of IGR group. Second, the Euro Heart Survey didn't report the separate analysis on the classification of patients based on OGTT or FPG only due to small sample size. But they did observe a higher prevalence of mortality in IFG and IGT patients, although the differences remained insignificant.
The present study also showed that in comparison with known diabetic CAD patients, the risk of death from all cause and CVD was a little higher in newly diagnosed diabetic patients. This might be because not all the newly diagnosed patients were patients with newly onset of diabetes.
Part of them had diabetes for a period of time but undiagnosed, which was proven by Chinese high undiagnosed rate of diabetes (2) . Lack of monitoring and control of glucose might partly explain the higher risk of mortality compared with known diabetic patients, 69% of whom took anti-diabetic drugs at baseline in our cohort. Moreover, our patients with newly diagnosed diabetes were severer with CAD and shared more harmful lifestyles. The rates of smoking and alcohol drinking were higher while the time of physical activity was less in patients with newly diagnosed diabetes.
Page 14 of 39 Diabetes Care
Since IGR, IFG and newly diagnosed diabetes have been confirmed as independent risk factors of death in our study and several others, we need to pay attention to CAD patients with hyperglycemia, especially those with pre-diabetes and newly diagnosed diabetes. IFG and IGT have been proven as high risk factors of developing diabetes, and they are considered as intermediate stages in any form of diabetes process (29, 30) . In addition, subjects with IFG and IGT are also related to many traditional CVD risk factors, such as obesity, dyslipidemia and hypertension. Recent studies have shown that the onset of diabetes can be prevented or delayed in subjects with prediabetes through lifestyle intervention and treatment with oral hypoglycemic agents, while lifestyle intervention is more effective than drugs (29) (30) (31) . Therefore, it is important to develop a screening strategy of glucose which is both practical and predictive to individuals who will benefit from early diagnosis and prevention of glucose abnormality. Our finding also raises the question whether directed glucose-lowering intervention might further improve clinical outcomes in CAD patients with hyperglycemia.
Several possible mechanisms may explain our results. Hyperglycemia itself may have direct cardiotoxicity which leads to worse prognosis in CAD patients. The effects include inducing electrophysiological alterations and fatal arrhythmias; reducing ischaemic pre-conditioning and resulting in worse myocardial performance; increasing thrombophilia; intensifying inflammatory immune reactions and worsening endothelial function (32) . All these processes are related with bad cardiac function and then contribute to adverse outcomes.
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There are some limitations in our present study. First, our subjects were enrolled from hospitals which may bring about selection bias. In general, in-patients are considered having severer disease status than non-hospitalized people. However, we included both acute CAD patients and those with stable manifestation, and some of them were elective admitted patients with mild status. Thus we can reduce the bias. Second, only part but not all of study samples conduct
OGTTs due to the clinical practice rituals and patients' will. To evaluate the impact of this shortcoming, we performed separate subgroup analyses in 1118 CAD patients with both FPG and 2-hour glucose measurements compared with 1724 CAD patients of our all study samples with full FPG measurements and part of 2-hour glucose measurements. In general, the significant associations of known and newly diagnosed diabetes with all-cause and CVD mortality were not influenced substantially. But the hazard ratios of IFG and IGT patients were statistically insignificant, which may be due to missing OGTTs of the high risk patients. Third, we cannot completely exclude the effects of residual confounding resulting from measurement error in the assessment of confounding factors or some unmeasured factors.
In conclusion, our study confirms that IFG, newly diagnosed diabetes, and known diabetes are all associated with increased risks of all-cause and CVD mortality among CAD patients, while patients with IGR had significantly higher risk for CVD mortality and marginally greater risk for all-cause mortality. Data are mean (standard error) or percentage, except duration of CAD is shown median (lower-upper quartiles); all continuous variables are adjusted for age and sex, except for age (adjusted for sex only). 
Page 27 of 39 Diabetes Care
Page 31 of 39 Diabetes Care
Multivariate-adjusted cumulative survival curves of all-cause (A) and CVD (B) mortality associated with both fasting and 2-hour glucose states. Adjusted for age, gender, education, marriage, leisure-time physical activity, smoking, alcohol drinking, type of CAD, severity of CAD, duration of CAD, treatment of CAD, history of heart failure, BMI, SBP, total cholesterol, HDL cholesterol, eGFR, use of antihypertensive drugs, use of cholesterol-lowering drugs, and use of antiplatelet drugs. 155x124mm (72 x 72 DPI)
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The line of newly diagnosed diabetes overlapped with the line of known diabetes in Figure 1B .
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